The Biology and Genetic Types of AGS
At a Glance
Aicardi-Goutières syndrome (AGS) is caused by genetic mutations that prevent cells from clearing out leftover DNA and RNA. The immune system mistakes this buildup for a virus, triggering chronic inflammation. The specific gene involved helps doctors predict symptoms and guide care for your child.
Understanding the biology of Aicardi-Goutières syndrome (AGS) begins with a “glitch” in how the body handles its own genetic material [1]. While we usually think of DNA and RNA as the building blocks of life, your child’s immune system sees these “self-nucleic acids” as a threat, triggering a constant state of internal “viral alarm” [2][3].
The “Self-Nucleic Acid” Glitch
In a typical cell, there is a constant process of creating and cleaning up tiny pieces of DNA and RNA. AGS is caused by a mutation in one of several genes that act like “cellular janitors” [1][4].
- The Job: Normally, these genes produce proteins that break down leftover pieces of DNA or RNA so the immune system never sees them [5][6].
- The Glitch: When these genes are mutated, the “trash” (self-nucleic acids) piles up inside the cell [7][6].
- The Alarm: A sensor in the cell (like cGAS or MDA5) finds this trash and mistakes it for a viral infection [5][8]. This triggers the release of Type I Interferon, a powerful chemical that causes the brain and body to stay in a state of high-alert inflammation [1][2].
Genetic Subtypes and What They Mean
The specific gene affected in your child (their genotype) often influences how the disease looks and progresses (their phenotype) [9][10]. While the most common genes are listed below, a small percentage of children may have a clinical diagnosis of AGS without an identified mutation [11][12].
| Affected Gene | Subtype | Common Associated Features |
|---|---|---|
| TREX1 | AGS1 | Often severe; early onset in the first weeks of life [10][9]. |
| RNASEH2B | AGS2 | Most common type; can be milder or progress more slowly; some children have preserved intellect [13][14]. |
| SAMHD1 | AGS5 | Higher risk for moyamoya (narrowing of brain blood vessels) and skin/joint issues [15][16]. |
| ADAR1 | AGS6 | Can cause skin pigment changes or sudden movement issues (striatal necrosis) later in childhood [17][18]. |
| IFIH1 | AGS7 | A “gain-of-function” mutation where the sensor itself is overactive; often involves severe skin, gut, or lung issues [19][20]. |
How It Is Inherited
AGS can be passed down in two main ways. Your genetic test results will specify which one applies to your family [21].
- Autosomal Recessive: This is the most common path [16]. Both parents are “carriers” of one mutated copy of the gene but have no symptoms themselves. For each pregnancy, there is a 25% (1 in 4) chance the child will inherit both mutated copies and have AGS [21].
- Autosomal Dominant: In this case, only one mutated copy of the gene is needed to cause the condition [21]. This can be inherited from one parent who also has the mutation, or it can be a “de novo” mutation, meaning it happened for the first time in the child and neither parent is a carrier [18][21].
Knowing the specific gene involved is the “roadmap” your doctors will use to monitor your child’s health, from checking their blood vessels to testing their thyroid or kidney function [22][23].
Common questions in this guide
What causes Aicardi-Goutières syndrome?
Does the specific AGS gene mutation my child has matter?
What is Type I Interferon's role in AGS?
How is AGS inherited?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Which specific AGS gene was identified in our child, and what is its normal role in the body?
- 2.Is our child's genetic mutation inherited in an autosomal recessive or autosomal dominant manner?
- 3.Based on this genotype (e.g., SAMHD1 or IFIH1), are there specific organs like the kidneys, heart, or blood vessels we should monitor more closely?
- 4.How does our child's specific mutation typically affect long-term developmental milestones compared to other types?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (23)
- 1
Aicardi-Goutières syndrome: A monogenic type I interferonopathy.
Liu A, Ying S
Scandinavian journal of immunology 2023; (98(4)):e13314 doi:10.1111/sji.13314.
PMID: 37515439 - 2
Generation of three induced pluripotent cell lines (iPSCs) from an Aicardi-Goutières syndrome (AGS) patient harboring a deletion in the genomic locus of the sterile alpha motif and HD domain containing protein 1 (SAMHD1).
Fuchs NV, Schieck M, Neuenkirch M, et al.
Stem cell research 2020; (43()):101697 doi:10.1016/j.scr.2019.101697.
PMID: 32062129 - 3
Aicardi-Goutières syndrome (AGS): recurrent fetal cardiomyopathy and pseudo-TORCH syndrome.
Panigrahy N, Bakhru S, Lingappa L, Chirla D
BMJ case reports 2022; (15(12)) doi:10.1136/bcr-2022-249192.
PMID: 36581356 - 4
The DNase TREX1 is a substrate of the intramembrane protease SPP with implications for disease pathogenesis.
Tever OK, Mentrup T, Chinn IK, et al.
Cellular and molecular life sciences : CMLS 2025; (82(1)):107 doi:10.1007/s00018-025-05645-5.
PMID: 40072623 - 5
Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling.
Shim A, Luan X, Zhou W, et al.
bioRxiv : the preprint server for biology 2024; doi:10.1101/2024.01.04.574136.
PMID: 38260344 - 6
A central role for PI3K-AKT signaling pathway in linking SAMHD1-deficiency to the type I interferon signature.
Oh C, Ryoo J, Park K, et al.
Scientific reports 2018; (8(1)):84 doi:10.1038/s41598-017-18308-8.
PMID: 29311560 - 7
Mutations in the non-catalytic polyproline motif destabilize TREX1 and amplify cGAS-STING signaling.
Shim A, Luan X, Zhou W, et al.
Human molecular genetics 2024; (33(18)):1555-1566 doi:10.1093/hmg/ddae089.
PMID: 38796715 - 8
ADAR1 interaction with Z-RNA promotes editing of endogenous double-stranded RNA and prevents MDA5-dependent immune activation.
de Reuver R, Dierick E, Wiernicki B, et al.
Cell reports 2021; (36(6)):109500 doi:10.1016/j.celrep.2021.109500.
PMID: 34380029 - 9
Developmental Outcomes of Aicardi Goutières Syndrome.
Adang L, Gavazzi F, De Simone M, et al.
Journal of child neurology 2020; (35(1)):7-16 doi:10.1177/0883073819870944.
PMID: 31559893 - 10
Exploration of Gross Motor Function in Aicardi-Goutières Syndrome.
Gavazzi F, Glanzman AM, Woidill S, et al.
Journal of child neurology 2023; (38(8-9)):518-527 doi:10.1177/08830738231188753.
PMID: 37499181 - 11
Phenotypic and Molecular Spectrum of Aicardi-Goutières Syndrome: A Study of 24 Patients.
Al Mutairi F, Alfadhel M, Nashabat M, et al.
Pediatric neurology 2018; (78()):35-40 doi:10.1016/j.pediatrneurol.2017.09.002.
PMID: 29239743 - 12
Nucleotide metabolism, leukodystrophies, and CNS pathology.
Gavazzi F, Gonzalez CD, Arnold K, et al.
Journal of inherited metabolic disease 2024; (47(5)):860-875 doi:10.1002/jimd.12721.
PMID: 38421058 - 13
Late diagnosis and atypical brain imaging of Aicardi-Goutières syndrome: are we failing to diagnose Aicardi-Goutières syndrome-2?
Svingen L, Goheen M, Godfrey R, et al.
Developmental medicine and child neurology 2017; (59(12)):1307-1311 doi:10.1111/dmcn.13509.
PMID: 28762473 - 14
Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.
Videira G, Malaquias MJ, Laranjinha I, et al.
Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.
PMID: 32258229 - 15
Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report.
Wu CC, Peng SS, Lee WT
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2020; (41(11)):3353-3356 doi:10.1007/s10072-020-04516-0.
PMID: 32524323 - 16
SAMHD1 compound heterozygous rare variants associated with moyamoya and mitral valve disease in the absence of other features of Aicardi-Goutières syndrome.
Karla AR, Pinard A, Boerio ML, et al.
American journal of medical genetics. Part A 2024; (194(4)):e63486 doi:10.1002/ajmg.a.63486.
PMID: 38041217 - 17
Case Report: Aicardi-Goutières Syndrome Type 6 and Dyschromatosis Symmetrica Hereditaria With Congenital Heart Disease and Mitral Valve Calcification - Phenotypic Variants Caused by Adenosine Deaminase Acting on the RNA 1 Gene Homozygous Mutations.
Liu L, Zhang L, Huang P, et al.
Frontiers in pediatrics 2022; (10()):852903 doi:10.3389/fped.2022.852903.
PMID: 35832578 - 18
Dyschromatosis symmetrica hereditaria: A clue to early diagnosis of Aicardi-Goutières syndrome.
Ahmed F, Do N, Vanderver AL, Treat JR
Pediatric dermatology 2024; (41(1)):156-157 doi:10.1111/pde.15437.
PMID: 37770123 - 19
Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes.
Bursztejn AC, Briggs TA, del Toro Duany Y, et al.
The British journal of dermatology 2015; (173(6)):1505-13 doi:10.1111/bjd.14073.
PMID: 26284909 - 20
Severe diarrhea in a 10-year-old girl with Aicardi-Goutières syndrome due to IFIH1 gene mutation.
Lu M, Zhu K, Zheng Q, et al.
American journal of medical genetics. Part A 2021; (185(10)):3146-3152 doi:10.1002/ajmg.a.62397.
PMID: 34189822 - 21
An overview of genetic mutations in Aicardi-Goutières syndrome in Iranian population.
Khalilian S, Fathi M, Miryounesi M, Ghafouri-Fard S
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(2)):999-1007 doi:10.1007/s10072-024-07824-x.
PMID: 39470906 - 22
Endocrinopathies in Aicardi Goutières syndrome-A descriptive case series.
Worth C, Briggs TA, Padidela R, et al.
Clinical case reports 2020; (8(11)):2181-2185 doi:10.1002/ccr3.3081.
PMID: 33235754 - 23
Collapsing Glomerulopathy as a Complication of Type I Interferon-Mediated Glomerulopathy in a Patient With RNASEH2B-Related Aicardi-Goutières Syndrome.
Fenaroli P, Rossi GM, Angelotti ML, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (78(5)):750-754 doi:10.1053/j.ajkd.2021.02.330.
PMID: 33872687
This page explains the genetics and biology of Aicardi-Goutières syndrome for educational purposes. Always consult a genetic counselor or pediatric neurologist to interpret your child's specific genetic test results.
Get notified when new evidence is published on Aicardi-Goutières syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.